SB
Samsara BioCapital Portfolio holdings
AUM
$489M
This Quarter Return
-15.81%
1 Year Return
+135.25%
3 Year Return
+909.96%
5 Year Return
+774.56%
10 Year Return
–
AUM
$478M
AUM Growth
+$478M
(-26%)
Cap. Flow
+$27.4M
Cap. Flow
% of AUM
5.73%
Top 10 Holdings %
Top 10 Hldgs %
73.56%
Holding
41
New
2
Increased
3
Reduced
3
Closed
1
Top Buys
| 1 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$23.2M |
| 2 |
CTNM
Contineum Therapeutics
CTNM
|
$10.4M |
| 3 |
CRGX
CARGO Therapeutics
CRGX
|
$4.83M |
| 4 |
Leap Therapeutics
LPTX
|
$3.48M |
| 5 |
Sutro Biopharma
STRO
|
$1.53M |
Top Sells
| 1 |
Janux Therapeutics
JANX
|
$5.66M |
| 2 |
Adverum Biotechnologies
ADVM
|
$4.12M |
| 3 |
Zymeworks
ZYME
|
$3.91M |
| 4 |
Immatics
IMTX
|
$2.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CRGX
1
DELISTED
CARGO Therapeutics
CRGX
| $72.5M | 15.17% | 4,415,689 +294,000 | +7% | +$4.83M |
|
2
Mineralys Therapeutics
MLYS
$1.03B
| $59.4M | 12.43% | 5,074,916 | – | – |
|
3
Scholar Rock
SRRK
$3.14B
| $56.5M | 11.84% | 6,788,609 | – | – |
|
4
Neurogene
NGNE
$264M
| $46.1M | 9.66% | 1,267,790 | – | – |
|
5
Arcellx
ACLX
$3.85B
| $25M | 5.24% | 453,641 | – | – |
|
|
CLYM
6
Climb Bio, Inc. Common Stock
CLYM
$151M
| $23.2M | 4.85% | +3,261,393 | New | +$23.2M |
|
7
Nkarta
NKTX
$151M
| $22.3M | 4.66% | 3,768,035 | – | – |
|
|
LENZ
8
LENZ Therapeutics
LENZ
$1.1B
| $20.9M | 4.37% | 1,208,473 | – | – |
|
|
AVDL
9
Avadel Pharmaceuticals
AVDL
$1.43B
| $13.6M | 2.85% | 967,527 | – | – |
|
10
Jasper Therapeutics
JSPR
$45.5M
| $11.9M | 2.49% | 525,000 | – | – |
|
11
HilleVax
HLVX
$105M
| $11.6M | 2.42% | 799,274 | – | – |
|
|
ABVX
12
Abivax
ABVX
$6.12B
| $11.2M | 2.35% | 850,000 | – | – |
|
|
SLRN
13
DELISTED
ACELYRIN
SLRN
| $11.1M | 2.33% | 2,523,022 | – | – |
|
|
CTNM
14
Contineum Therapeutics
CTNM
$293M
| $10.4M | 2.17% | +588,817 | New | +$10.4M |
|
|
SYRS
15
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $9.22M | 1.93% | 1,786,427 | – | – |
|
|
16
Zymeworks
ZYME
$1.12B
| $8.51M | 1.78% | 1,000,000 -458,875 | -31% | -$3.91M |
|
17
Rhythm Pharmaceuticals
RYTM
$6.85B
| $7.09M | 1.48% | 172,647 | – | – |
|
|
INZY
18
DELISTED
Inozyme Pharma
INZY
| $6.97M | 1.46% | 1,562,500 | – | – |
|
|
19
Sutro Biopharma
STRO
$72.7M
| $6.44M | 1.35% | 2,196,814 +521,235 | +31% | +$1.53M |
|
20
Gossamer Bio
GOSS
$562M
| $5.52M | 1.16% | 6,130,268 | – | – |
|
21
Tango Therapeutics
TNGX
$747M
| $5.41M | 1.13% | 630,000 | – | – |
|
|
VRNA
22
Verona Pharma
VRNA
$9.16B
| $5.02M | 1.05% | 347,500 | – | – |
|
|
23
Leap Therapeutics
LPTX
$12M
| $4.79M | 1% | 2,442,352 +1,773,049 | +265% | +$3.48M |
|
24
IO Biotech
IOBT
$104M
| $4.26M | 0.89% | 3,640,015 | – | – |
|
25
vTv Therapeutics
VTVT
| $3.65M | 0.76% | 206,784 | – | – |
|